Early withdrawal of calcineurin inhibitors and everolimus monotherapy in de novo liver transplant recipients preserves renal function

American Journal of Transplantation

Volumn 10, Issue 10, 2010, Pages 2252-2262

  Masetti, M ^a   Montalti, R ^a   Rompianesi, G ^a   Codeluppi, M ^a   Gerring, R ^b   Romano, A ^a   Begliomini, B ^a   Di Benedetto, F ^a   Gerunda, G E ^a  

^a UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^b UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

Cyclosporine; everolimus; liver transplantation; renal function; renal impairment

Indexed keywords

BASILIXIMAB; CYCLOSPORIN A; EVEROLIMUS; GANCICLOVIR; METHYLPREDNISOLONE SODIUM SUCCINATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE;

ADULT; ARTERY OCCLUSION; ARTERY THROMBOSIS; ARTICLE; BILIARY TRACT DISEASE; CHRONIC KIDNEY DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOMEGALOVIRUS INFECTION; DIETARY INTAKE; DRUG BLOOD LEVEL; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; GLOMERULUS FILTRATION RATE; GRAFT RECIPIENT; HEPATIC ARTERY STENOSIS; HEPATIC ARTERY THROMBOSIS; HUMAN; INCIDENCE; INCISIONAL HERNIA; INFECTION; INFECTION PREVENTION; KIDNEY FUNCTION; LIVER GRAFT; LIVER GRAFT REJECTION; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; PERIPHERAL EDEMA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SURVIVAL RATE;

EID: 77957192348     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/j.1600-6143.2010.03128.x     Document Type: Article

References (34)

1. Ojo AO, Held PJ, Port FK et al. Chronic renal failure after transplantation of a nonrenal organ. N Engl J Med 2003 349: 931 940. (Pubitemid 37064766)
2. Gonwa TA, Mai ML, Melton LB et al. End-stage renal disease (ESRD) after orthotopic liver transplantation (OLTX) using calcineurin-based immunotherapy: Risk of development and treatment. Transplantation 2001 72: 1934 1939.
3. Morard I, Mentha G, Spahr L et al. Long-term renal function after liver transplantation is related to calcineurin inhibitors blood levels. Clin Transplant 2006 20: 96 101. (Pubitemid 43349033)
4. Kim DY, Lim C, Parasuraman R et al. Renal disease burden following liver transplantation. Transplant Proc 2006 38: 3663 3665. (Pubitemid 44908441)
5. Dunn C, Croom KF. Everolimus: A review of its use in renal and cardiac transplantation. Drugs 2006 66: 547 570.
6. De Simone P, Carrai P, Precisi A et al. Conversion to everolimus monotherapy in maintenance liver transplantation: Feasibility, safety, and impact on renal function. Transpl Int 2009 22: 279 286.
7. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: A new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 1999 130: 461 470.
8. Rule AD, Larson TS, Bergstralh EJ, Slezak JM, Jacobsen SJ, Cosio FG. Using serum creatinine to estimate glomerular filtration rate: Accuracy in good health and in chronic kidney disease. Ann Intern Med 2004 141: 929 937.
9. Board NKFNKDOQIKDA. K/DOQI clinical practice guidelines for chronic kidney disease: Evaluation, classification and stratification. Am J Kidney Dis 2002 39: S1 S246.
10. Banff schema for grading liver allograft rejection: An international consensus document. Hepatology 1997 25: 658 663.
11. Khoschsorur G, Fruehwirth F, Zelzer S, Stettin M, Halwachs-Baumann G. Comparison of fluorescent polarization immunoassay (FPIA) versus HPLC to measure everolimus blood concentrations in clinical transplantation. Clin Chim Acta 2007 380: 217 221. (Pubitemid 46498038)
12. Arzu GD, De Ruvo N, Montalti R et al. Temporary porto-caval shunt utility during orthotopic liver transplantation. Transplant Proc 2008 40: 1937 1940.
13. Masetti M, Rompianesi G, Montalti R et al. Effects of everolimus monotherapy on hematological parameters and iron homeostasis in de novo liver transplant recipients: Preliminary results. Transplant Proc 2008 40: 1947 1949.
14. Schlitt HJ, Barkmann A, Boker KH et al. Replacement of calcineurin inhibitors with mycophenolate mofetil in liver-transplant patients with renal dysfunction: A randomised controlled study. Lancet 2001 357: 587 591. (Pubitemid 32179611)
15. Burdmann EA, Andoh TF, Yu L, Bennett WM. Cyclosporine nephrotoxicity. Semin Nephrol 2003 23: 465 476. (Pubitemid 37176692)
16. Fisher NC, Nightingale PG, Gunson BK, Lipkin GW, Neuberger JM. Chronic renal failure following liver transplantation: A retrospective analysis. Transplantation 1998 66: 59 66. (Pubitemid 28341169)
17. Stewart SF, Hudson M, Talbot D, Manas D, Day CP. Mycophenolate mofetil monotherapy in liver transplantation. Lancet 2001 357: 609 610. (Pubitemid 32179620)
18. Chang GJ, Mahanty HD, Quan D et al. Experience with the use of sirolimus in liver transplantation-use in patients for whom calcineurin inhibitors are contraindicated. Liver Transpl 2000 6: 734 740.
19. Kniepeiss D, Iberer F, Grasser B, Schaffellner S, Tscheliessnigg KH. Sirolimus and mycophenolate mofetil after liver transplantation. Transpl Int 2003 16: 504 509. (Pubitemid 36975570)
20. Cotterell AH, Fisher RA, King AL et al. Calcineurin inhibitor-induced chronic nephrotoxicity in liver transplant patients is reversible using rapamycin as the primary immunosuppressive agent. Clin Transplant 2002 16 (Suppl 7 49 51.
21. Nair S, Eason J, Loss G. Sirolimus monotherapy in nephrotoxicity due to calcineurin inhibitors in liver transplant recipients. Liver Transpl 2003 9: 126 129. (Pubitemid 36204562)
22. Fairbanks KD, Eustace JA, Fine D, Thuluvath PJ. Renal function improves in liver transplant recipients when switched from a calcineurin inhibitor to sirolimus. Liver Transpl 2003 9: 1079 1085. (Pubitemid 37304464)
23. Morard I, Dumortier J, Spahr L et al. Conversion to sirolimus-based immunosuppression in maintenance liver transplantation patients. Liver Transpl 2007 13: 658 664. (Pubitemid 46796536)
24. Yang YJ, Li LX, He Q et al. Sirolimus as primary immunosuppressant for calcineurin inhibitor-related renal insufficiency after liver transplantation. Hepatobiliary Pancreat Dis Int 2007 6: 376 378. (Pubitemid 47288120)
25. Shenoy S, Hardinger KL, Crippin J et al. Sirolimus conversion in liver transplant recipients with renal dysfunction: A prospective, randomized, single-center trial. Transplantation 2007 83: 1389 1392. (Pubitemid 46800318)
26. Watson CJ, Gimson AE, Alexander GJ et al. A randomized controlled trial of late conversion from calcineurin inhibitor (CNI)-based to sirolimus-based immunosuppression in liver transplant recipients with impaired renal function. Liver Transpl 2007 13: 1694 1702.
27. DuBay D, Smith RJ, Qiu KG, Levy GA, Lilly L, Therapondos G. Sirolimus in liver transplant recipients with renal dysfunction offers no advantage over low-dose calcineurin inhibitor regimens. Liver Transpl 2008 14: 651 659. (Pubitemid 351696277)
28. Greig P, Lilly L, Scudamore C et al. Early steroid withdrawal after liver transplantation: The Canadian tacrolimus versus microemulsion cyclosporin A trial: 1-year follow-up. Liver Transpl 2003 9: 587 595. (Pubitemid 36701695)
29. Amodio P, Biancardi A, Montagnese S et al. Neurological complications after orthotopic liver transplantation. Dig Liver Dis 2007 39: 740 747. (Pubitemid 47046640)
30. Montalbano M, Neff GW, Yamashiki N et al. A retrospective review of liver transplant patients treated with sirolimus from a single center: An analysis of sirolimus-related complications. Transplantation 2004 78: 264 268. (Pubitemid 39525348)
31. Watson CJ, Friend PJ, Jamieson NV et al. Sirolimus: A potent new immunosuppressant for liver transplantation. Transplantation 1999 67: 505 509. (Pubitemid 29114208)
32. Levy G, Schmidli H, Punch J et al. Safety, tolerability, and efficacy of everolimus in de novo liver transplant recipients: 12- and 36-month results. Liver Transpl 2006 12: 1640 1648. (Pubitemid 44742543)
33. O'Grady JG, Burroughs A, Hardy P, Elbourne D, Truesdale A. Tacrolimus versus microemulsified ciclosporin in liver transplantation: The TMC randomised controlled trial. Lancet 2002 360: 1119 1125.
34. Oo YH, Dudley T, Nightingale P, Haydon G, Mutimer D. Tacrolimus and cyclosporin doses and blood levels in hepatitis C and alcoholic liver disease patients after liver transplantation. Liver Transpl 2008 14: 81 87. (Pubitemid 351167993)